Ad
related to: new antipsychotic approved products today
Search results
Results from the WOW.Com Content Network
Antipsychotics can cause weight gain, drowsiness, metabolic syndrome, which can increase risk of heart attack or stroke, or involuntary movements such as blinking or sticking out your tongue.
Antipsychotics by class Generic name Brand names Chemical class ATC code Typical antipsychotics; Acepromazine: Atravet, Acezine: phenothiazine: N05AA04
Saphris – atypical antipsychotic used to treat schizophrenia and bipolar disorder; Serax – anti-anxiety medication of the benzodiazepine class, often used to help during detoxification from alcohol or other addictive substances; Serentil (mesoridazine) – an antipsychotic drug used in the treatment of schizophrenia [1]
Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the butyrophenone class. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy (with lithium or valproate). [2] It is developed by Intra-Cellular Therapies, licensed from Bristol ...
NEW YORK (AP) — Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal.
Unlike other antipsychotics, pimavanserin is not a dopamine receptor antagonist, [5] but rather is a selective antagonist or inverse agonist of the serotonin 5-HT 2A receptor and to a lesser extent of the serotonin 5-HT 2C receptor. [3] Pimavanserin was first approved for medical use in 2016. [3] It was approved as a generic medication in 2024. [6]
Tiotixene, or thiothixene is a typical antipsychotic agent currently sold under the brand name Navane which is predominantly utilised to treat acute and chronic schizophrenia. [2] Beyond its primary indication , it can exhibit a variety of effects common to neuroleptic drugs including anxiolytic , anti-depressive, and anti-aggressive properties.
Ulotaront (INN Tooltip International Nonproprietary Name; [1] developmental codes SEP-363856, SEP-856) is an investigational antipsychotic that is undergoing clinical trials for the treatment of schizophrenia and Parkinson's disease psychosis.
Ad
related to: new antipsychotic approved products today